Orai3 orchestrates gemcitabine resistance in pancreatic cancer via NFATc1-SLIT3 axis
Samriddhi AroraiD, Abhishek TanwariD, Gyan RanjaniD, Rajender K. MotianiiD
Abstract
Pancreatic Cancer (PC) is one of the most aggressive cancers and is associated with poor prognosis. Gemcitabine is the first-line chemotherapy for PC. While gemcitabine-based regimes offer survival benefits, the acquired gemcitabine resistance leads to reoccurrence, metastasis and the long-term survival rate remains dismal. Although there is substantial clinical evidence for gemcitabine resistance, the cellular and molecular mechanisms driving gemcitabine resistance remain largely unappreciated. Here, we reveal that Orai3, a Ca2+ selective channel, is a crucial driver of gemcitabine resistance. We demonstrate that Orai3 is upregulated in gemcitabine-resistant PC cells. Orai3 silencing in these cells decreases proliferation, induces cell cycle arrest, enhances apoptosis, and moderates stemness characteristics. Notably, studies in zebrafish model corroborate the significance of Orai3 in gemcitabine resistance in vivo. Mechanistically, our unbiased RNA-seq analysis coupled with robust functional studies show that SLIT3 works downstream of Orai3 to drive gemcitabine resistance. Finally, we report that NFATc1 transcription factor bridges Orai3 to SLIT3 transcription. Taken together, this study identifies Orai3 as a key orchestrator of gemcitabine resistance and uncovers a unique Orai3-NFATc1-SLIT3 signaling module that drives chemoresistance. Hence, this work reveals Orai3 as a promising target for synergistic therapeutic approach to combat chemoresistance. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=197 HEIGHT=200 SRC="FIGDIR/small/671673v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@16fea2org.highwire.dtl.DTLVardef@1a77a3forg.highwire.dtl.DTLVardef@4aef28org.highwire.dtl.DTLVardef@19b62a3_HPS_FORMAT_FIGEXP M_FIG C_FIG Highlights{Rightarrow} Orai3 is upregulated in gemcitabine-resistant pancreatic cancer cells {Rightarrow}Orai3 is essential for chemo-sensitivity, migration, invasion and stemness in vitro {Rightarrow}Orai3 regulates metastasis of gemcitabine-resistant pancreatic cancer cells in vivo {Rightarrow}Unbiased RNA-seq reveals that SLIT3 functions downstream of Orai3 to drive gemcitabine resistance {Rightarrow}NFATc1 transcription factor bridges Orai3 to SLIT3 transcription
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TGF-βRII knock-down promotes tumor growth and chemoresistance to gemcitabine of pancreatic cancer cells via phosphorylation of STAT3
V. Drubay, N. Skrypek, … N. Jonckheere·bioRxiv·Jun 21, 2018
- Characterization and implication of the Orai3 channel and ABC type transporters in the phenomenon of chemoresistance to cisplatin and pemetrexed in lung cancer.
Rédoane Daoudi·bioRxiv·Sep 22, 2024
- Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response
Stefanie Höfer, Larissa Frasch, … Bernhard Küster·Molecular Systems BiologyPeer-reviewed·Jan 21, 2025
- Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer
Caitlin Molczyk, Reegan Sturgeon, … Rakesh K. Singh·FASEB BioAdvancesPeer-reviewed·Jan 1, 2026
- Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer
Alica K. Beutel, Sabrina E. Calderon, … Christopher J. Halbrook·bioRxiv·Sep 19, 2025
- Inositol Polyphosphate-4-Phosphatase Type II promotes gemcitabine resistance in pancreatic ductal adenocarcinoma cells via lysosomal exocytosis
Ché M.P. Melo, Candaice A. Newell, … Leonardo Salmena·bioRxiv·Aug 24, 2026